Professor | 王迎庆 | 数字化转型顾问

Name

王迎庆

Contact Information

yqwang@simm.ac.cn

Language ability

中文, 英语

Province

上海

University/Lab Affiliation and Title	中国科学院大学
Faculty	Medical School
Academic Background & Achievements	2008-10到2010-12 联合培养博士: 瑞典Karolinska医学院 2007-09到2010-12 博士: 吉林大学 2004-09到2007-06 硕士: 吉林大学 2000-09到2004-06 学士: 吉林大学
Work Experience	2013-10到2016-06 - 中国科学院上海药物研究所 - 副研究员 2013-07到2013-09 - 中国科学院上海药物研究所 - 助理研究员 2011-05到2013-06 - 中国科学院上海药物研究所 - 博士后 2008-10到2010-12 - 瑞典Karolinska医学院 - 联合培养博士 2007-09到2010-12 - 吉林大学 - 博士 2004-09到2007-06 - 吉林大学 - 硕士 2000-09到2004-06 - 吉林大学 - 学士

University/Lab Affiliation and Title

中国科学院大学

Faculty

Medical School

Academic Background & Achievements

Work Experience

Areas of Focus	药理学肿瘤药理学
Publications	Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities, 第9作者, 2022 Discovery of a series of 1H-pyrrolo2,3-bpyridine compounds as potent TNIK inhibitors, 第4作者, 2021 Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1, 第9作者, 2021 A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction, 第12作者, 2020 Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter, 第4作者, 2020 Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors, 第17作者, 2019 Inhibition of the BET family reduces its new target gene IDO1 expression and the production of l -kynurenine, 第8作者, 2019 New microtubulin inhibitor MT189 suppresses angiogenesis via the JNK-VEGF/VEGFR2 signaling axis, 第7作者, 2018 Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties, 第6作者, 2018 New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and

Areas of Focus

药理学
肿瘤药理学

Publications

Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities, 第9作者, 2022
Discovery of a series of 1H-pyrrolo2,3-bpyridine compounds as potent TNIK inhibitors, 第4作者, 2021
Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1, 第9作者, 2021
A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction, 第12作者, 2020
Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter, 第4作者, 2020
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors, 第17作者, 2019
Inhibition of the BET family reduces its new target gene IDO1 expression and the production of l -kynurenine, 第8作者, 2019
New microtubulin inhibitor MT189 suppresses angiogenesis via the JNK-VEGF/VEGFR2 signaling axis, 第7作者, 2018
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties, 第6作者, 2018
New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and

药理学肿瘤癌症药物开发化疗分子生物学细胞生物学临床试验治疗学

任斌 - 武汉大学

Area of Focus
脊柱 | 骨骼 | 肿瘤 | 肿瘤学 | 手术 | 治疗 | 研究 | 临床试验 | 医疗保健 | 医学

黄勇 - 武汉大学

张红艳 - 武汉大学

View All

Personal Information